The conversion of fibroblasts into tumor-homing-personalized induced neural stem cells (iNSCs) is a promising approach for treating various types of cancer. We combine functional, genomic, and in vivo assays to investigate the efficacy and tumor-homing capacity of the first iNSCs derived from brain cancer patients, marking an important step toward clinical application.
